RxSight Q1 revenue $29.5M (+69% YoY), raises FY2024 guidance

RxSight, Inc.

2024-Q1 EPS reported -$0.25 revenue$29,512,000

LAL volume up 92% to 20,218 units; LDD installed base reaches 732 (+61% YoY).
Gross margin expands to 70% from 59% on favorable mix and lower production costs.
Net loss narrows to $9.1M ($0.25/share) from $13.2M ($0.42); adjusted loss $4.4M ($0.12).
Raises FY2024 revenue guidance to $132-137M (from $128-135M) and gross margin to 68-70%.
Cash remains strong at $125.4M, down slightly from $127.2M at year-end.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

RxSight, Inc. reported the three months ended March 31, 2024 results: revenue $29.5 million, net income $(9.1) million, EPS $(0.25) per basic and diluted share. Guidance raised.

Period: the three months ended March 31, 2024
Revenue: $29.5 million
Net income: $(9.1) million
EPS: $(0.25) per basic and diluted share
Guidance: raised
Result: reported results

Exact text from the filing

following cataract surgery, today reported financial results for the three months ended March 31, 2024. Key Quarterly Highlights • Reported first quarter 2024 revenue of $29.5 million, an increase of 69% compared to the first quarter of 2023, reflecting: • The sale of 20,218 Light Adjustable Lenses (LAL®/LAL+TM), representing a 92% increase in procedure volume

View on SEC.gov

710 earnings releases filed in the last 30 days. Browse all earnings releases →

RxSight, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-24-053553

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.